Patient preferences for antiretroviral therapy: effectiveness, quality of life, access and novel delivery methods

Figures & data

Table 1 Summary of participant demographics

Participant	NGT session	Age (years)	Race/ethnicity	Gender	Recruitment	Time on ART (years)	Current regimen
1	1	72	H	M**	Staff referred	7	Efavirenz/emtricitabine/tenofovir*
2	1	39	H	M**	Staff referred	<1	Ritonavir/darunavir/emtricitabine/tenofovir
3	1	40	H	F	Staff referred	3	Ritonavir/darunavir/emtricitabine/tenofovir
4	1	52	H	M	Staff referred	<1	Cobicistat/elvitegravir/emtricitabine/tenofovir*
5	1	42	H	M	Staff referred	2	Cobicistat/elvitegravir/emtricitabine/tenofovir*
6	1	25	H	M	Staff referred	3	Cobicistat/elvitegravir/emtricitabine/tenofovir*
7	1	28	H	M**	Staff referred	6	Ritonavir/lopinavir/emtricitabine/tenofovir*
8	1	44	H	M**	Staff referred	6	Efavirenz/emtricitabine/tenofovir*
9	2	38	B	F	Screen	6	Cobicistat/elvitegravir/emtricitabine/tenofovir*
10	2	47	B	F	Flyer	9	Cobicistat/elvitegravir/emtricitabine/tenofovir*
11	2	56	B	F	Flyer	10	Abacavir/lamivudine/dolutegravir*
12	2	48	B	M	Flyer	1	Cobicistat/elvitegravir/emtricitabine/tenofovir*
13	2	27*	B	M	Staff referred	2	Cobicistat/elvitegravir/emtricitabine/tenofovir*
14	2	56	B	F	Flyer	8	Emtricitabine/tenofovir/rilpivirine*
15	2	41	B	F	Flyer	3	Cobicistat/elvitegravir/emtricitabine/tenofovir*
16	3	29	H	M	Staff referred	1	Cobicistat/elvitegravir/emtricitabine/tenofovir*
17	3	54	H	M	Staff referred	3	Cobicistat/elvitegravir/emtricitabine/tenofovir*
18	3	48	H	M	Staff referred	7	Efavirenz/emtricitabine/tenofovir*
19	3	31	H	M	Staff referred	3	Cobicistat/elvitegravir/emtricitabine/tenofovir*
20	4	48	B	F	Screen	10	Ritonavir/darunavir/dolutegravir
21	4	53	W	F	Flyer	10	Efavirenz/lamivudine/raltegravir
22	4	48	B	F	Staff referred	5	Ritonavir/darunavir/emtricitabine/tenofovir
23	4	38	B	TF**	Flyer	6	Ritonavir/darunavir/emtricitabine/tenofovir
24	4	45	B	F	Screen	6	Emtricitabine/tenofovir/rilpivirine*
25	4	25	B	M**	Flyer	10	Cobicistat/evitegravir/emtricitabine/tenofovir*
26	4	44	B	TF**	Screen	7	Cobicistat/elvitegravir/emtricitabine/tenofovir*
27	4	52	B	M**	Flyer	1	Emtricitabine/tenofovir/rilpivirine*
28	4	32	B	M	Flyer	10	Cobicistat/elvitegravir/emtricitabine/tenofovir*

Notes:

* Denotes current regimen is a single tablet formulation. Screen refers to patient recruited after viewing flyer on clinic’s Electronic Screen.

** Denotes M or TF reporting sex with men.

Abbreviations: ART, antiretroviral therapy; H, Hispanic; B, Black; W, White; M, male; F, female; TF, transgender female; NGT, nominal group technique.

Table 2 Preferences of persons living with HIV in relation to antiretroviral therapy

Response to question 1	Category	Response score	Category score
Control virus	Clinical	66	162
Cure virus	Clinical	55	162
Minimize organ damage	Clinical	26	162
Improve CD4	Clinical	15	162
Feel better	Quality of life	40	120
Improve health	Quality of life	30	120
Minimize side effects	Quality of life	27	120
Sleep better	Quality of life	12	120
Prevent HIV symptoms	Quality of life	11	120
Supply vitamins/minerals	Pharmacologic	16	52
Long-acting	Pharmacologic	14	52
Dosing frequency	Pharmacologic	12	52
Taste better	Pharmacologic	10	52
Response to question 2	Category	Response score	Category score
No cure	Clinical	52	149
Damage organs	Clinical	49	149
Drug failure	Clinical	38	149
HIV resistance	Clinical	10	149
Minimize side effects	Quality of life	62	62
Cost	Access	41	78
Ability to get care	Access	37	78
Drug interactions	Pharmacologic	11	11

Notes: Question 1: “What do you want this medicine to do for you?” Question 2: “What are your concerns about taking this medicine?” Scores are based on rank-order assigned by patients ranging from 5 points (most important) to 1 point (least important).